Agios Pharmaceuticals (NASDAQ:AGIO) Stock Price Expected to Rise, Truist Financial Analyst Says

Agios Pharmaceuticals (NASDAQ:AGIO) had its target price lifted by Truist Financial from $32.00 to $38.00 in a report issued on Wednesday, MarketBeat reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Truist Financial’s price objective points to a potential upside of 31.49% from the stock’s current price.

A number of other equities research analysts have also recently issued reports on the company. Leerink Partnrs upgraded Agios Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Thursday, November 20th. Bank of America upped their price target on shares of Agios Pharmaceuticals from $32.00 to $34.00 and gave the stock a “buy” rating in a research report on Wednesday. Zacks Research raised shares of Agios Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Tuesday, November 4th. HC Wainwright lowered their price objective on shares of Agios Pharmaceuticals from $56.00 to $48.00 and set a “buy” rating on the stock in a research note on Thursday, November 20th. Finally, Leerink Partners upgraded shares of Agios Pharmaceuticals from a “market perform” rating to an “outperform” rating and cut their target price for the company from $40.00 to $34.00 in a research note on Thursday, November 20th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Agios Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $38.22.

Agios Pharmaceuticals Price Performance

Agios Pharmaceuticals stock opened at $28.90 on Wednesday. The company has a market cap of $1.69 billion, a price-to-earnings ratio of -4.13 and a beta of 0.87. The firm has a 50-day moving average of $34.03 and a 200-day moving average of $36.26. Agios Pharmaceuticals has a one year low of $22.24 and a one year high of $46.00.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.78) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.93) by $0.15. Agios Pharmaceuticals had a negative return on equity of 28.35% and a negative net margin of 895.86%.The business had revenue of $12.88 million for the quarter, compared to the consensus estimate of $10.49 million. During the same quarter in the previous year, the business earned $16.22 earnings per share. Agios Pharmaceuticals’s quarterly revenue was up 43.3% on a year-over-year basis. As a group, sell-side analysts expect that Agios Pharmaceuticals will post -6.85 earnings per share for the current year.

Insider Transactions at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, insider Sarah Gheuens sold 3,302 shares of the firm’s stock in a transaction that occurred on Monday, October 27th. The shares were sold at an average price of $43.92, for a total transaction of $145,023.84. Following the completion of the sale, the insider directly owned 61,727 shares in the company, valued at $2,711,049.84. This trade represents a 5.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders have sold 3,902 shares of company stock worth $170,754 in the last three months. Company insiders own 4.30% of the company’s stock.

Hedge Funds Weigh In On Agios Pharmaceuticals

A number of large investors have recently made changes to their positions in the company. Marshall Wace LLP boosted its stake in shares of Agios Pharmaceuticals by 31.4% in the 2nd quarter. Marshall Wace LLP now owns 684,669 shares of the biopharmaceutical company’s stock valued at $22,772,000 after purchasing an additional 163,796 shares in the last quarter. Assenagon Asset Management S.A. bought a new position in shares of Agios Pharmaceuticals in the 3rd quarter valued at $2,696,000. Frazier Life Sciences Management L.P. boosted its holdings in shares of Agios Pharmaceuticals by 19.6% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 1,279,754 shares of the biopharmaceutical company’s stock valued at $42,565,000 after acquiring an additional 209,900 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its position in Agios Pharmaceuticals by 30.7% during the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 505,225 shares of the biopharmaceutical company’s stock worth $16,804,000 after acquiring an additional 118,702 shares during the last quarter. Finally, Boothbay Fund Management LLC increased its holdings in Agios Pharmaceuticals by 71.1% in the 2nd quarter. Boothbay Fund Management LLC now owns 447,019 shares of the biopharmaceutical company’s stock worth $14,868,000 after purchasing an additional 185,798 shares in the last quarter.

More Agios Pharmaceuticals News

Here are the key news stories impacting Agios Pharmaceuticals this week:

• Positive Sentiment: FDA approval: AQVESME (mitapivat) received FDA approval for anemia in adults with alpha‑ and beta‑thalassemia — making mitapivat the only approved oral therapy for these thalassemia types and opening a new commercial market for Agios. Business Insider: FDA Approves AQVESME
• Positive Sentiment: Regulatory detail & safety program: Approval includes a REMS/labeling requirement but confirms the indication expansion that investors had been anticipating, increasing near‑term revenue visibility. Zacks: Mitapivat Gets FDA Nod with REMS
• Positive Sentiment: Analyst upgrades/price target increases: Bank of America bumped its target to $34 (buy) and Truist raised its target to $38 and reiterated a buy — analysts cite the new indication as a revenue catalyst. Yahoo Finance: Price Target Raised
• Positive Sentiment: Commercial pricing and market expectation: Reports indicate list/pricing intentions near ~$425k per patient per year, which, combined with the exclusive oral label, supports material revenue potential if uptake and reimbursement follow. MSN: Pricing Report
• Neutral Sentiment: Media & transcript coverage: Multiple writeups, press releases and an investor/transcript slide deck circulated summarizing the approval and commercial plan — useful context for investors but incremental to the headline approval. Seeking Alpha: Approval Transcript
• Neutral Sentiment: Trading action: Shares were temporarily halted for a news release ahead of the announcement and volume spiked as the approval and analyst reactions hit the tape — heightened liquidity can amplify intraday moves.
• Negative Sentiment: Safety/label limitation: The approval includes a boxed warning/REMS for potential liver injury — this safety profile may temper prescribing, restrict use, and complicate commercial uptake. Seeking Alpha: Analysis and Risks
• Negative Sentiment: Revenue ceiling and payer risk: Several analysts/notes flag that thalassemia peak sales estimates (~$500M) may not be enough by itself to drive profitability; high list price could trigger payer restrictions or access delays. Seeking Alpha: Commercial Outlook
• Neutral Sentiment: Short interest note: Recent short‑interest data in the feed is anomalous/zero and likely not informative; monitor later filings for accurate short positioning.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.